CIK 0001035354
- Non-accelerated filer
- Smaller reporting company
Eloxx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELOX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 841368850
- Phone
- +1 781-577-5300
- Business address
- P.O. BOX 274, ARLINGTON, MA, 02476
- Former names
- Sevion Therapeutics, Inc., SENESCO TECHNOLOGIES INC, NAVA LEISURE USA INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-10 | Aggarwal Sumit President and CEO | Grant or award · Stock Option (Right to Buy) | +328,833 | 328,833 | ||
| 2026-02-28 | Aggarwal Sumit President and CEO | Exercise or conversion | +260,946 | $0.15 | $39K | 1,672,756 |
| 2026-02-28 | Aggarwal Sumit President and CEO | Exercise or conversion · Stock Option (Right to Buy) | −260,946 | 3,336,144 | ||
| 2026-01-24 | Aggarwal Sumit President and CEO | Exercise or conversion | +15,000 | 1,411,810 | ||
| 2026-01-24 | Aggarwal Sumit President and CEO | Exercise or conversion · Restricted Stock Units | −15,000 | 15,000 | ||
| 2025-09-19 | Aggarwal Sumit President and CEO | Grant or award | +1,000,000 | 1,396,810 | ||
| 2025-09-19 | Aggarwal Sumit President and CEO | Grant or award · Stock Option (Right to Buy) | +3,597,090 | 3,597,090 | ||
| 2025-08-14 | Aggarwal Sumit President and CEO | Exercise or conversion | +196,880 | $0.00 | $20 | 396,810 |
| 2025-08-14 | Aggarwal Sumit President and CEO | Exercise or conversion · Stock Option (Right to Buy) | −60,390 | 0 | ||
| 2025-08-14 | Aggarwal Sumit President and CEO | Exercise or conversion · Stock Option (Right to Buy) | −68,700 | 0 | ||
| 2025-08-14 | Aggarwal Sumit President and CEO | Exercise or conversion · Stock Option (Right to Buy) | −25,000 | 0 | ||
| 2025-08-14 | Aggarwal Sumit President and CEO | Exercise or conversion · Stock Option (Right to Buy) | −42,790 | 0 | ||
| 2025-01-24 | Aggarwal Sumit Director | Exercise or conversion | +30,000 | 199,930 | ||
| 2025-01-24 | Aggarwal Sumit Director | Exercise or conversion · Restricted Stock Units | −30,000 | 30,000 | ||
| 2024-10-16 | Aggarwal Sumit President and CEO | Returned to the company · Stock Option (Right to Buy) | −42,790 | 0 | ||
| 2024-10-16 | Aggarwal Sumit President and CEO | Grant or award · Stock Option (Right to Buy) | +42,790 | 42,790 | ||
| 2024-10-16 | Aggarwal Sumit President and CEO | Returned to the company · Stock Option (Right to Buy) | −35,580 | 0 | ||
| 2024-10-16 | Aggarwal Sumit President and CEO | Grant or award · Stock Option (Right to Buy) | +35,580 | 35,580 | ||
| 2024-10-16 | Aggarwal Sumit President and CEO | Returned to the company · Stock Option (Right to Buy) | −24,810 | 0 | ||
| 2024-10-16 | Aggarwal Sumit President and CEO | Grant or award · Stock Option (Right to Buy) | +24,810 | 24,810 |
Page 1 of 2 · 33 trades